Ceftriaxone in the treatment of solid tumour patients with febrile neutropenia

Onkologie

Volumn 21, Issue 3, 1998, Pages 212-216

  Karthaus, M ^a   Wolf, H H ^b   Egerer, G ^c   Kampfe D ^d   Suedhoff, T ^e   Ritter, J ^f   Jurgens H ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Medizinische Klinik

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Ceftriaxone; Febrile low risk neutropenia; Febrile neutropenia; Monotherapy; Solid tumours

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTRIAXONE; GLYCOPEPTIDE; METRONIDAZOLE;

ADOLESCENT; ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA; CHILD; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; ENTEROCOCCUS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SKIN MANIFESTATION; SOLID TUMOR;

EID: 0031850280     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026814     Document Type: Article

References (28)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
2. Klastersky J: Empiric treatment of infection during granulocytopema. Ann Oncol 1990;1:255-261.
3. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-573
4. Calandra T, Zinner S, Viscoli C, De Bock R, Gaya H, Meunier F, Klastersky J, Glauser M: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-593.
5. Fauser AA, Lang E, Kochling G, Daschner FD: A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 1994;22:271-275.
6. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
7. Hathorn JW. Pizzo PA: Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother 1986;17(suppl A):41-54.
8. Biron P, Fuhrmann C, Kheder R, Viens P, Lefebvre D, Beal J, Thyss A, Viot M, Soler-Michel P, Rollin C. Gres JJ: Cefipime versus imipenem-cilastin as empiric monotherapy in 400 febrile patients with short duration of neutropenia. 37th ICAAC, Toronto, 1997; LM-48 (Abstract).
9. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:5 52-558.
10. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, Glauser M: Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group Antimicrob Agents Chemother 1991;35: 873-878
11. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995;98:224-231.
12. Smith L, Will AM, Williams RF, Stevens RF: Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990;20 201-206
13. Blanc C, Pollet JP, Bauters F Ceftriaxone plus Amikacin in Neutropenic Patients: A Report on 100 Cases. Chemotherapy 1991:37:382-388.
14. Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-1115.
15. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C: Empiric antimicrobial therapy for febrile granulocytopenic cancer patients, lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24 Suppl 1:S35-45.
16. Winston DJ, Ho WG, Bruckner DA, Champlin RE: Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-859.
17. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332
18. Charnas R, Ridolfi Luthi A, Ruch W: Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Paediatr Infect Dis J 1997;16:346-353.
19. Malik IA, Khan WA, Aziz Z, Karim M: Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 1994;19:522-527.
20. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J MedSci 1994;30:649-651
21. Rubenstein EB, Rolston K: Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 1994;2:369-373.
22. Petrilli AS, Melaragno R, Barros KV, Silva AA, Kusano E, Ribeiro RC, Bianchi A: Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease Pediatr Infect Dis J 1993;12: 916-921.
23. Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters WP Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994;12:1005-1011
24. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12:107-114.
25. Khaliq Y, Bence-Bruckler I, Bresdesoq C, van der Jagt R, McDiarmid SA, Huebsch LB: Once daily ceftriaxone for febrile neutropenia in an outpatient blood & marrow transplant programme. Blood 1996;86:837, 212a (abstract)
26. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, et al: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71 3640-3646.
27. Rolston K: Outpatient management of fever in neutropenic patients. Curr Opin Infect Dis 1996;9:407-410.
28. Freifeld AG, Pizzo PA: The outpatient management of febrile neutropenia in cancer patients. Oncology (Huntingt) 1996;10:599-606.